

Supplemental Table 5. Association between *TMPRSS2:ERG* fusion and prostate cancer outcomes broken out by assay used to assess fusion status (radical prostatectomy specimens only), results from the meta-analysis

Outcome	RR Stage \geq pT3 (95% CI) # Cohorts	RR Gleason > 7 (95% CI) # Cohorts	RR Recurrence (95% CI) # Cohorts	RR Mortality (95% CI) # Cohorts	WMD Age (95% CI) # Cohorts
<i>Assay</i>					
FISH	1.15 (1.04, 1.27) 17	0.80 (0.67, 0.95) 15	0.98 (0.78, 1.22) 7	1.91 (0.97, 3.78) 3	-0.55 (-2.12, 1.01) 6
RT-PCR	1.19 (1.06, 1.33) 12	0.94 (0.65, 1.37) 11	1.18 (0.76, 1.84) 9	0.20 (0.06, 0.67) 1	-0.72 (-2.11, 0.68) 7
IHC	1.29 (1.19, 1.40) 4	0.82 (0.51, 1.32) 4	0.99 (0.88, 1.11) 3	1.00 (0.66, 1.50) 1 ^a	-0.93 (-1.73, -0.13) 2
<i>P for Effect Modification by Assay</i>					
	0.09	0.62	0.95	0.58	0.47

Abbreviations: FISH – Fluorescence In Situ Hybridization; IHC – Immunohistochemistry; RR – Risk Ratio; RT-PCR – Reverse Transcription Polymerase Chain Reaction; WMD – Weighted Mean Difference

^a Only includes data from PHS / HPFS